Itrazole capsules 100mg №6

Dosage form

Capsules

Composition

1 capsule contains 100 mg of itraconazole

Packaging

14 pcs.

Mechanism of action

Intrazol is a synthetic broad-spectrum antifungal agent. The triazole derivative. Suppresses the synthesis of ergosterol cell membrane of fungi. It is active against dermatophytes (Trichophyton spp., Microsporum spp., Epidermophyton floccosum), and yeast fungi Candida spp. (including Candida albicans, Candida glabrata, Candida krusei), mold fungi (Cryptococcus neoformans, Aspergillus spp., Histoplasma spp., Paracoccidioides braziliensis, Sporothrix schenckii, Fonsecae spp., Cladosporium spp., etc., etc., etc., etc., etc.). The effectiveness of treatment is assessed after 2-4 weeks after cessation of therapy (for mycoses), after 6-9 months for onychomycosis (as the nails change).

Indications and usage

• Mycoses of the skin, oral mucosa and eyes;
• onychomycosis caused by dermatophytes, yeasts and molds;
• candidiasis with damage to the skin and mucous membranes, incl. vulvovaginal candidiasis;
• pityriasis versicolor;
• systemic mycoses, incl. aspergillosis (with resistance or poor tolerance to amphotericin B),
• cryptococcosis (including cryptococcal meningitis),
• histoplasmosis, sporotrichosis, paracoccidioidomycosis, blastomycosis.

Contraindications

Hypersensitivity, pregnancy, lactation.

Dosage and administration

Itrazole capsules are taken orally after meals.
Onychomycosis - 200 mg once a day for 3 months or 200 mg 2 times a day for 1 week, followed by a break of 3 weeks; with onychomycosis of the feet, 3 courses of treatment are recommended, brushes - 2 courses;
Vulvovaginal candidiasis- 200 mg 2 times for 1 day or 200 mg 1 time per day for 3 days; Pityriasis versicolor - 200 mg 1 time per day for 7 days;
Dermatomycosis and oral candidiasis - 100-200 mg 1 time per day for 7-15 days (if necessary, repeat the course);
Fungal keratitis - 200 mg once a day for 21 days; Systemic mycoses - 100-200 mg 1-2 times a day for 2-12 months (depending on the pathogen).

Adverse reactions

On the part of the gastrointestinal tract: dyspepsia, nausea, abdominal pain, anorexia, vomiting, constipation, increased transaminase activity of the liver, hepatitis, in very rare cases - severe toxic liver damage, incl. case of acute liver failure with a fatal outcome.
From the nervous system and sensory organs: headache, dizziness, peripheral neuropathy, fatigue, drowsiness.
Since the cardiovascular system and blood (blood, hemostasis): arterial hypertension. Cases of chronic heart failure associated with taking itraconazole have been reported.
From the side genitourinary system: dysmenorrhea, edematous syndrome, albuminuria, dark-colored urine staining.Allergic reactions: pruritus, rash, urticaria, angioedema, Stevens-Johnson syndrome.Other: alopecia, hypokalemia, pulmonary edema, decreased libido, impotence.

Cautions

In patients with impaired immunity (AIDS, after organ transplantation, neutropenia), an increase in dose may be required.Patients with cirrhosis of the liver and / or renal failure, with increased activity of liver transaminases Itraconazole is prescribed under the control of its concentration in plasma and only in cases where the expected effect of therapy exceeds the possible risk of liver damage. With a duration of administration of more than 1 month, control of liver function is necessary. Women of reproductive age during the period of treatment should use contraceptive methods. With the development of abnormal liver function or peripheral neuropathy, itraconazole should be abolished.

Drug Interactions

Incompatible with terfenadine, astemizole, cisapride, lovastatin, oral forms of midazolam and triazolam. Strengthens and / or prolongs the action of oral anticoagulants (including warfarin), cyclosporine, Digoxin, methylprednisolone, vincristine, Calcium channel blockers. Rifampicin and phenytoin reduce the bioavailability of itraconazole, and cytochrome CYP3A4 inhibitors (ritonavir, indinavir, clarithromycin) increase its bioavailability. Antacid drugs reduce the absorption of itraconazole (the interval separating their intake should be at least 2 hours).

Overdosage

Treatment:gastric lavage, reception of Activated carbon, symptomatic therapy. Not removed during hemodialysis. There is no specific antidote.

Storage conditions

In a dry, dark place at a temperature below 25 °